Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck

NICE technology appraisals [TA172] Published date:

Cetuximab in combination with platinum-based chemotherapy is not recommended for people with recurrent and/or metastatic squamous cell cancer of the head and neck.

Healthcare professionals should not stop prescribing cetuximab in combination with platinum-based chemotherapy for people who were already taking it when the guidance was issued. These people should be able to carry on taking cetuximab until they and their healthcare professionals decide that it is the right time to stop treatment.

Get involved